Brain Cancer Drugs Market Research Reports

Brain & CNS Cancer Forecast in 19 Major Markets 2016-2026 - Product Thumbnail Image

Brain & CNS Cancer Forecast in 19 Major Markets 2016-2026

  • Report
  • 66 Pages
From
Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation - Product Thumbnail Image

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • Report
  • 73 Pages
From
Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors - Product Thumbnail Image

Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors

  • Book
  • 478 Pages
CAS Cyclophosphamide World Consumption Report - Product Thumbnail Image

CAS Cyclophosphamide World Consumption Report

  • Report
  • 2091 Pages
CAS Methotrexate World Consumption Report - Product Thumbnail Image

CAS Methotrexate World Consumption Report

  • Report
  • 2095 Pages
CAS 15663-27-1 Cisplatin Chemical World Report - Product Thumbnail Image

CAS 15663-27-1 Cisplatin Chemical World Report

  • Report
  • 2157 Pages
CAS 159351-69-6 Everolimus Chemical World Report - Product Thumbnail Image

CAS 159351-69-6 Everolimus Chemical World Report

  • Report
  • 2075 Pages
CAS 59-05-2 Methotrexate Chemical World Report - Product Thumbnail Image

CAS 59-05-2 Methotrexate Chemical World Report

  • Report
  • 2111 Pages
CAS 6055-19-2 Cyclophosphamide monohydrate Chemical World Report - Product Thumbnail Image

CAS 6055-19-2 Cyclophosphamide monohydrate Chemical World Report

  • Report
  • 2001 Pages
CAS 7413-34-5 Sodium methotrexate Chemical World Report - Product Thumbnail Image

CAS 7413-34-5 Sodium methotrexate Chemical World Report

  • Report
  • 2006 Pages
CAS 50-18-0 Cyclophosphamide Chemical World Report - Product Thumbnail Image

CAS 50-18-0 Cyclophosphamide Chemical World Report

  • Report
  • 2011 Pages
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Pipeline Review, H1 2018 - Product Thumbnail Image

Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Pipeline Review, H1 2018

  • Report
  • 50 Pages
From
Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy. Edition No. 2 - Product Thumbnail Image

Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy. Edition No. 2

  • Book
  • 848 Pages
Market Spotlight: Neuroendocrine tumors (NET) - Product Thumbnail Image

Market Spotlight: Neuroendocrine tumors (NET)

  • Report
  • 42 Pages
From
Global Brain Cancer Partnering 2012 to 2018 - Product Thumbnail Image

Global Brain Cancer Partnering 2012 to 2018

  • Report
  • 150 Pages
From
Neuroblastoma Pipeline Highlights - 2018 - Product Thumbnail Image

Neuroblastoma Pipeline Highlights - 2018

  • Report
From
Glioma Pipeline Highlights - 2018 - Product Thumbnail Image

Glioma Pipeline Highlights - 2018

  • Report
From
Brain Cancer Pipeline Highlights - 2018 - Product Thumbnail Image

Brain Cancer Pipeline Highlights - 2018

  • Report
From
Glioblastoma Pipeline Highlights - 2018 - Product Thumbnail Image

Glioblastoma Pipeline Highlights - 2018

  • Report
From
Global Brain Cancer Epidemiology and Patient Flow Analysis - 2018 - Product Thumbnail Image

Global Brain Cancer Epidemiology and Patient Flow Analysis - 2018

  • Report
From
Loading Indicator

With low survival rates primary brain cancers such as glioblastoma multiforme (the most common and aggressive of malignant brain tumours) are among the deadliest forms of cancer. Drug development activity is therefore intense in this sector, with resulting business development opportunities. Reports in the Brain Cancer section enable you to explore various facets of the industry from a variety of expert viewpoints, including R&D (clinical trials, drug discovery, etc.), competitive landscape, supply and demand, regional markets, regional market analysis, and much more. Show Less Read more

adroll